• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma's $462 Billion of M&As Since Jan 2014


April 27, 2015.

Today's Financial Times (FT) reports

that, since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions - greater than the gross domestic product of Austria.   In a piece entitled "No end in sight to wave of pharma dealmaking", and following the latest advances by Teva to make a bid for Mylan, Andrew Ward asks "What is driving the frenzy?"   According to Jeremy Levin, former chief executive of Teva, the most impetus has been financial rather than strategic.   For more on this story,

click here


Related Videos